三鑫醫療(300453.SZ):擬將成都威力生59.75%股權轉讓給四川威力生
格隆匯7月15日丨三鑫醫療(300453.SZ)公佈,公司於2021年7月15日召開第四屆董事會第十一次會議,審議通過了《關於向全資子公司轉讓控股子公司股權的議案》,基於公司血液淨化業務產業化佈局的需要,為進一步優化資源配置,提高管理效率,同意公司以取得成都威力生生物科技有限公司(“成都威力生”)59.75%股權的投資成本為依據,將該股權作價4240.76萬元全部轉讓給公司全資子公司四川威力生醫療科技有限公司(“四川威力生”)。
此次股權轉讓完成後,四川威力生將持有成都威力生59.75%股權,公司不再直接持有成都威力生股權,成都威力生將成為公司全資子公司四川威力生的控股子公司,公司合併報表範圍不發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.